
Ardelyx Inc
ARDXHealthcare|Biotechnology|USA
$5.28
-0.10 (-1.77%)
Tangible Book
$0.60
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
543.72,
740.18,
985.22,
1271.93,
1446.52
],
"ebit_estimate": [
13.07,
157.46,
351.07,
579.01,
730.01
],
"ebitda_estimate": [
12.87,
163.16,
353.13,
468.14,
546.09
],
"net_income_estimate": [
-13.21,
124.5,
298.69,
474.41,
591.99
],
"per_share_eps_estimate": [
-0.05,
0.46,
1.08,
1.79,
2.27
],
"eps_nri_estimate": [
-0.06,
0.48,
1.14,
1.79,
2.27
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-13.44,
148.5,
336.12,
570.41,
717.75
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-15.75,
53.66,
59.91,
null,
null
],
"gross_margin_estimate": [
95.37,
95.44,
95.6,
95.6,
95
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
11.43,
4.88,
2.95,
2.33
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "34.42",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 34.42,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 1.74,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
126.77,
149.95,
172.48,
130.13,
170.49,
198.69,
225.95
],
"ebit_estimate": [
-4.14,
14.57,
34.37,
-10.24,
25.11,
48.77,
70.78
],
"ebitda_estimate": [
1.01,
14.63,
25.41,
null,
null,
null,
null
],
"net_income_estimate": [
-9.39,
8.61,
25,
-14.75,
19.16,
41.03,
60.06
],
"per_share_eps_estimate": [
-0.04,
0.04,
0.1,
-0.06,
0.08,
0.16,
0.24
],
"eps_nri_estimate": [
-0.04,
0.03,
0.1,
-0.07,
0.08,
0.16,
0.24
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-9.15,
8.93,
24.37,
-7.99,
26.7,
48.24,
64.32
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-31.04,
7.17,
38.88,
null,
null,
null,
null
],
"gross_margin_estimate": [
94.95,
95.55,
95.9,
95,
95,
95,
95
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
182.07,
35.44,
19.06,
12.69,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "34.42",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 34.42,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 1.74,
"future_operating_cash_flow_per_share_estimate_growth": null
}